RAXAR
LOE ApproachingNDAORALTABLET
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAXAR is an oral tablet NDA-approved small molecule developed by Otsuka and launched in 1997. The mechanism of action, pharmacologic class, and specific indications are not publicly detailed in available data. Patient population and therapeutic positioning require additional clinical documentation.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams are likely in transition or consolidation mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RAXAR currently has zero linked open positions and minimal commercial momentum as it approaches loss of exclusivity. Career opportunity is constrained; roles would focus on legacy management, generic transition planning, or niche market optimization.
Company
Worked on RAXAR at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.